Fig. 3
The characterization of LILRB4 transgenic mice have been evaluated under normal conditions after generation. (A) Overview of the construction scheme for microglia LILRB4 knockout and overexpression mouse models. (B) qPCR was used to detect the level of LILRB4 transcription in mice brain. (n = 6; *p = 0.0127, **p = 0.0018). (C) FACS analysis of LILRB4 expression in microglia from LILRB4-KO, LILRB4-TG and Control mice. (n = 6; *p < 0.05). (D) Quantitative data plot in (C). (n = 6; ****p<0.0001). (E) Body weight of LILRB4-KO, LILRB4-TG and Control mice. (n = 6; p = 0.9973). (F) Quantitation and statistical evaluation of Rotarod test, Noval Object Recognition and Tail suspension test for the normal LILRB4-KO, LILRB4-TG and Control mice. (n = 6; p = 0.8803/0.4642/0.9887). (G) Representative immunohistochemical staining for neurons, astrocytes, microglia in brain sections from normal LILRB4-KO, LILRB4-TG and Control mice after tamoxifen injecton (7 days after the last dose). (H) Neurons (anti-NeuN, red), astrocytes (anti-GFAP, green) and microglia (anti-Iba-1, green) were quantified with DAPI counterstain (blue). (n = 6; p = 0.9479/0.3929/4557). (I) HE staining revealed no obvious inflammatory infiltration in brain sections of Control, LILRB4-KO or LILRB4-TG mice under normal conditions. (4x, Scale bar, 200 μm; 20x, Scale bar, 40 μm)